Effects of GLP-1 RAs on Weight and Metabolic Indicators in Obese Patients

Sponsor
Xiangya Hospital of Central South University
Study ID
NCT03671733
Phase
PHASE3
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Not accepted

Interventions

  • Liraglutide — DRUG
    The treatment of Liraglutide lasted three months,During the first week: 0.6mg per day, subcutaneous injection;During the second week: 1.2mg per day, subcutaneous injection; From third week onwards, 1.8mg per day, subcutaneous injection.
  • Exenatide — DRUG
    10mcg once a day for 4 weeks increased to 10mcg twice a day for 8 weeks.
  • Exenatide Microspheres for Injection — DRUG
    Exenatide 2 mg injection once weekly for 12 weeks.

Study Details

This studay evaluates the effect of the glucagon-like peptide-1 (GLP-1) receptor agonist,including Liraglutide,Exenatide and Exenatide Microspheres for Injection,in the treatment of subjects who are overweight or obese.

Key Dates

Start date
Sep 1, 2018
Status verified
Apr 2021
Primary completion
Sep 1, 2022
Completion
Sep 1, 2022

Study Design

Enrollment
150 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Liraglutide
    Administered subcutaneously (s.c., under the skin) once daily for 12 weeks.
  • Experimental: Exenatide
    Administered subcutaneously (s.c., under the skin) twice daily for 12 weeks.
  • Experimental: Exenatide Microspheres for Injection
    Administered subcutaneously (s.c., under the skin) once weekly for 12 weeks.

Primary Outcome Measure

Weight Change at 3 months [ Time Frame: baseline , 3 months ]

Central Contacts

Related Studies